Strong Ph III data for Indevus' Sanctura XR

16 July 2006

US drugmaker Indevus Pharmaceuticals says that Sanctura XR (trospium Cl), the once-daily formulation of its currently-marketed overactive bladder drug, met the primary endpoints in the second of two Phase III trials. According to the firm, the anticholinergic reduced the frequency of urination and the number of urge incontinence episodes.

The randomized, double-blind, placebo-controlled trial also achieved all of its key secondary endpoints, including an increase in void volume and a reduction in the severity of urgency, a defining symptom of OAB. Glenn Cooper, Indevus' chief executive, stated that, in the two Phase III trials, Sanctura XR has set a "new tolerability benchmark for oral drugs in the treatment of OAB," with an overall dry mouth incidence of 10.7%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.